Innate Pharma Doses First Patient in Phase 1 Trial of Pioneering ADC

Innate Pharma SA reported that the initial patient has been dosed in its Phase 1 trial (NCT06781983), evaluating the safety and tolerability of IPH4502, a novel Antibody-Drug Conjugate (ADC), in individuals with advanced solid tumors expressing Nectin-4.

IPH4502 is a unique and distinct ADC that acts as a topoisomerase I inhibitor, specifically engineered to target Nectin-4. This cell adhesion molecule is highly expressed in various solid tumors, such as urothelial carcinoma (UC), breast cancer, non-small cell lung cancer, and gastrointestinal cancer. IPH4502 aims at tumors displaying varied Nectin-4 expression, facilitating its advancement beyond UC. The IPH4502 distinct topoisomerase I inhibiting payload enhances its promise for patients whose tumors are resistant to MMAE-ADC.

“We are thrilled to initiate the Phase 1 study with IPH4502, a promising therapy for patients with advanced solid tumors known to express Nectin-4,” said Dr Shiraj Sen, Medical Oncologist and Phase 1 Investigator, Director of Clinical Research, NEXT Oncology-Dallas. “IPH4502 is uniquely designed to target tumors with both high and low expression of Nectin-4, offering hope for improved outcomes in a population where effective treatment options are limited, and relapses occur frequently. This study represents an important step forward in advancing innovative care for these patients.”